278 related articles for article (PubMed ID: 17595663)
1. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Ueno H; Kiyosawa K; Kaniwa N
Br J Cancer; 2007 Jul; 97(2):145-51. PubMed ID: 17595663
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology and pharmacogenetics of gemcitabine.
Wong A; Soo RA; Yong WP; Innocenti F
Drug Metab Rev; 2009; 41(2):77-88. PubMed ID: 19514966
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in the treatment of metastatic pancreatic cancer.
Hilbig A; Oettle H
Expert Rev Anticancer Ther; 2008 Apr; 8(4):511-23. PubMed ID: 18402518
[TBL] [Abstract][Full Text] [Related]
4. [Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
Lokiec F; Lansiaux A
Bull Cancer; 2007; 94 Spec No Actualites():S85-9. PubMed ID: 17845976
[TBL] [Abstract][Full Text] [Related]
5. Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Chen X; Zhang L; Ren S; Li X; Zhou F; Li W; Gao G; He Y; Zhou C
Med Oncol; 2014 Apr; 31(4):865. PubMed ID: 24535606
[TBL] [Abstract][Full Text] [Related]
6. [The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
Mohelníková-Duchonová B; Soucek P
Klin Onkol; 2010; 23(5):306-10. PubMed ID: 21061681
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Danesi R; Altavilla G; Giovannetti E; Rosell R
Pharmacogenomics; 2009 Jan; 10(1):69-80. PubMed ID: 19102717
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Rosell R; Crino L; Danenberg K; Scagliotti G; Bepler G; Taron M; Alberola V; Provencio M; Camps C; De Marinis F; Sanchez JJ; Peñas R
Semin Oncol; 2003 Aug; 30(4 Suppl 10):19-25. PubMed ID: 12917817
[TBL] [Abstract][Full Text] [Related]
9. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
10. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Koay EJ; Truty MJ; Cristini V; Thomas RM; Chen R; Chatterjee D; Kang Y; Bhosale PR; Tamm EP; Crane CH; Javle M; Katz MH; Gottumukkala VN; Rozner MA; Shen H; Lee JE; Wang H; Chen Y; Plunkett W; Abbruzzese JL; Wolff RA; Varadhachary GR; Ferrari M; Fleming JB
J Clin Invest; 2014 Apr; 124(4):1525-36. PubMed ID: 24614108
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
12. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
13. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
14. [Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Jordheim LP; Galmarini CM; Dumontet C
Bull Cancer; 2005 Mar; 92(3):239-48. PubMed ID: 15820918
[TBL] [Abstract][Full Text] [Related]
15. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
16. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
17. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
Sehouli J
Int J Gynecol Cancer; 2005; 15 Suppl 1():23-30. PubMed ID: 15839955
[TBL] [Abstract][Full Text] [Related]
18. Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Ciccolini J; Mercier C; Dahan L; André N
Nat Rev Clin Oncol; 2011 Feb; 8(7):439-44. PubMed ID: 21304503
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine: a cytidine analogue active against solid tumors.
Hui YF; Reitz J
Am J Health Syst Pharm; 1997 Jan; 54(2):162-70; quiz 197-8. PubMed ID: 9117804
[TBL] [Abstract][Full Text] [Related]
20. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
